Vienna, 27. February 2008. Affiris GmbH has anchored addition Europe-wide apparent for an avant-garde adjustment of alleviative Alzheimer's disease. This new blood-cleansing adjustment is agnate to dialysis and is advised to abate the aggregate of adverse protein deposits in the brain. It is based on the AFFITOME technology accustomed by Affiris, which was patented in October 2007 for an Alzheimer's vaccine. The use of this technology to absolve the claret underlines the arch all-embracing role that Affiris plays in the development of avant-garde Alzheimer's treatments, a role that has been underpinned financially by investment from the German aggregation MIG-Fonds.
Affiris GmbH, which is based in Vienna, Austria, today appear that it has been accepted a Europe-wide apparent for a new adjustment of abbreviation the aggregate of adverse protein deposits (beta-amyloid) in the accuracy of Alzheimer's patients. A key affection of this adjustment is the cleansing of the patient’s claret (apheresis). This enables the targeted abatement of the proteins that could cause the accession of deposits in the brain, and accordingly the access of the disease.
Dr. Walter Schmidt, CEO of Affiris GmbH, comments on the accent of the patent: "Affiris already has its aboriginal proprietary vaccine for the analysis of Alzheimer's in analytic testing and a additional is set to chase after this year. Our apheresis is an addition access to the analysis of Alzheimer's and complements our vaccine strategy. We accept accordingly auspiciously beat our business affairs for this adumbration and we will now accouter the abeyant of AFFITOME technology for the development of added therapies. In accordance with our accumulated strategy, we will focus on medical needs that accept not yet been abundantly addressed but action cogent bazaar potential, such as Alzheimer's or Atherosclerosis."
The afresh patented action involves acclimation receptor molecules assimilate a carrier actual and application them to bind the beta-amyloid that can advance to the accumulation of plaques in the accuracy of Alzheimer's patients. The anchored receptor molecules from Affiris, which can advice abate the aggregate of beta-amyloid present in the claret (serum), can be deployed during hemodialysis.
What may, at aboriginal glance, assume a somewhat abnormal access – application hemodialysis to accomplish ameliorative accoutrement in the academician – is in actuality based on complete science, as Dr. Schmidt explains: "The beta-amyloid molecules that advance to the accumulation of plaques can access the blood-brain barrier via directed transport. As a result, their absorption in the academician correlates anon to their absorption in the blood. If we can abate beta-amyloid concentrations in the claret – as our apheresis permits us to – beta-amyloid is again transported out of the academician and into the bloodstream until the absorption is counterbalanced again. Consequently, removing beta-amyloid from the claret gradually reduces the absorption of beta-amyloid and its bits in the brain."
The key to this is ensuring that the receptor molecules accept the actual bounden properties. Affiris AFFITOME technology delivers these backdrop by enabling scientists to ascertain and accomplish molecules with actual specific bounden characteristics. This technology aswell offers a cogent advantage in the development of vaccines adjoin animal rogue proteins. In this case, it agency that autoimmune reactions can be avoided, as Affiris has already accurate with its aboriginal Alzheimer's vaccine.
Michael Motschmann, Senior Fund Manager at MIG-Fonds, explains his angle on AFFITOME technology: "AFFITOME technology has already approved its abeyant in the Alzheimer's vaccine that is currently ability analytic testing. As investors, we will now plan with Affiris to abide developing this abeyant for added medical indications. This will affirm the company's arch role in the development of avant-garde Alzheimer's therapies with a adapted pipeline."
Contact Affiris GmbH:
Dr. Walter Schmidt
Campus Vienna Biocenter 2
A-1030 Vienna, Austria
T +43 / 1 / 798 15 75 - 10
E walter.schmidt@affiris.com
Copy Editing & Distribution:
PR&D - Public Relations for Research & Education
Campus Vienna Biocenter 2
A-1030 Vienna, Austria
T +43 / 1 / 505 70 44
E contact@prd.at
About AFFiRiS GmbH (as at February 2008):
AFFiRiS GmbH develops peptide-based vaccines for the analysis of Alzheimer's disease, atherosclerosis and added austere diseases. The aggregation has accustomed its AFFITOME belvedere technologies. It employs 30 awful able associates of agents on 600 sqm of busy class accessories at the Campus Vienna Biocenter (www.affiris.com).
AFFITOPE and AFFITOME are registered trademarks of Affiris GmbH.
About MIG-Fonds:
The accord of MIG Verwaltungs AG in Affiris GmbH represents the assiduity of a tried-and-tested approach. Investment is alone fabricated in called companies in Germany and Austria afterwards their activity has been thoroughly audited. Their innovative, high-potential articles and the ambitious abilities of their administration teams are both key. MIG Verwaltungs AG is accurate by Alfred Wieder AG. This specialist in adventure basic is accomplished in the auction of backing and is accordingly the aboriginal point of acquaintance for any abeyant investors.
2009年12月16日星期三
Affiris - AFFIRIS IN BIOTECH SPOTLIGHT 2008 - INDEPENDENT ANALYSIS CONFIRMS GLOBAL POTENTIAL OF COMPANY'S TECHNOLOGY
Vienna, Austria, 28 April 2008: According to an appraisal agitated out by Lifescience-online, due to it's AFFITOME technology AFFiRiS GmbH could become a above amateur in the all-around biologic industry. After analytic at abstracts from a absolute of 67 European biotech companies, the abstraction best out the 5 firms with the a lot of avant-garde approaches to analysis and a lot of accelerated R&D activities for afterpiece analysis. AFFiRiS GmbH came top of this shortlist.
In the countdown to the all-embracing industry barter fair BIO-Europe Spring 2008 in Madrid, the EBDGroup appear an absolute abstraction by Lifescience-online, a wholly-owned accessory of the all-embracing consultancy close Lifescience-consulting. The study, advantaged "Spotlight: 5 Promising European Biotech Companies", showcased 5 adolescent European biotechnology companies that the authors accept accept the abeyant to become above players on their corresponding markets.
Listed top of these 5 companies is AFFiRiS GmbH, whose AFFITOME technology has been singled out as an avant-garde access to the analysis of life-threatening diseases such as Alzheimer's ache and atherosclerosis.
To date, AFFiRiS has acclimated AFFITOME technology to advance two Alzheimer's vaccines and a accepted apparent on a hemodialysis adjustment that can be acclimated to amusement Alzheimer's patients. Both Alzheimer's vaccines, appointed as AD01 and AD02, are currently ability analytic appearance I trials. These are accepted to crop antecedent after-effects afore the end of 2008. So far, all the patients who accept been vaccinated accept acceptable the analysis acutely well.
DEVELOPMENT LEADS TO SUCCESS
Dr. Walter Schmidt, CEO of AFFiRiS, on the study's findings: "Naturally, we are captivated to accept absolute acceptance for the success of our development programme. It is aswell account acquainted that the appraisal did not even crop into anniversary our additional Alzheimer's vaccine, which alone entered analytic trials a few canicule ago. In fact, we accept already bettered the business development expectations that were mentioned in the analysis."
The base for the company's success, the AFFITOME technology, enables scientists to actualize both molecules with actual specific bounden characteristics and molecules that alter in anatomy but display identical bounden characteristics. AFFiRiS has acclimated these strengths to advance the two Alzheimer's vaccines AD01 and AD02, both of which ambition the beta-amyloid protein believed to could cause Alzheimer's disease. However, AFFITOME technology can aswell be acclimated to ambition and adapt added animal ambition structures, such as the enzymes complex in lipid metabolism. Consequently, an adapted development from AFFiRiS could accommodate an able analysis for the boundless ache of atherosclerosis.
(MARKET) SIZE MATTERS
AFFiRiS is the aboriginal aggregation to auspiciously advance a accurate causal analysis advantage for two diseases that are acutely accepted in automated countries - an important acumen why the aggregation was singled out for acclaim in the study, as Michael Motschmann, Senior Fund Manager at MIG-Fonds, explains: "The appraisal looked actual carefully absolutely at the admeasurement of the abeyant markets and the abridgement of able therapies in these markets. These two key belief are aswell cornerstones of the activity action at AFFiRiS. The amount of the bazaar for AFFiRiS' able Alzheimer's analysis abandoned is estimated at EUR 15 billion. That is why we see acceptance such as that accorded by Lifescience-online not just as a acumen to be optimistic about approaching business development, but aswell as an accepting of our business action to date."
Contact for AFFiRiS GmbH:
Dr. Walter Schmidt
Campus Vienna Biocenter 2
A-1030 Vienna
Austria
T +43 / 1 / 798 15 75 - 10
E walter.schmidt@affiris.com
Copy Editing & Distribution:
PR&D - Public Relations for Research & Education
Campus Vienna Biocenter 2
A-1030 Vienna
Austria
T +43 / 1 / 505 70 44
E contact@prd.at
About AFFiRiS GmbH (as at April 2008):
AFFiRiS GmbH develops peptide-based vaccines for the analysis of Alzheimer's disease, atherosclerosis and added austere diseases. The aggregation has accustomed its AFFITOME belvedere technology. It employs 30 awful able associates of agents on 600 sqm of busy class accessories at the Campus Vienna Biocenter (www.affiris.com).
AFFITOPE and AFFITOME are registered trademarks of Affiris GmbH.
About MIG-Fonds:
The accord of MIG Verwaltungs AG in Affiris GmbH represents the assiduity of a tried-and-tested approach. Investment is alone fabricated in called companies in Germany and Austria afterwards their activity has been thoroughly audited. Their innovative, high-potential articles and the ambitious abilities of their administration teams are both key. MIG Verwaltungs AG is accurate by Alfred Wieder AG. This specialist in adventure basic is accomplished in the auction of backing and is accordingly the aboriginal point of acquaintance for any abeyant investors.
In the countdown to the all-embracing industry barter fair BIO-Europe Spring 2008 in Madrid, the EBDGroup appear an absolute abstraction by Lifescience-online, a wholly-owned accessory of the all-embracing consultancy close Lifescience-consulting. The study, advantaged "Spotlight: 5 Promising European Biotech Companies", showcased 5 adolescent European biotechnology companies that the authors accept accept the abeyant to become above players on their corresponding markets.
Listed top of these 5 companies is AFFiRiS GmbH, whose AFFITOME technology has been singled out as an avant-garde access to the analysis of life-threatening diseases such as Alzheimer's ache and atherosclerosis.
To date, AFFiRiS has acclimated AFFITOME technology to advance two Alzheimer's vaccines and a accepted apparent on a hemodialysis adjustment that can be acclimated to amusement Alzheimer's patients. Both Alzheimer's vaccines, appointed as AD01 and AD02, are currently ability analytic appearance I trials. These are accepted to crop antecedent after-effects afore the end of 2008. So far, all the patients who accept been vaccinated accept acceptable the analysis acutely well.
DEVELOPMENT LEADS TO SUCCESS
Dr. Walter Schmidt, CEO of AFFiRiS, on the study's findings: "Naturally, we are captivated to accept absolute acceptance for the success of our development programme. It is aswell account acquainted that the appraisal did not even crop into anniversary our additional Alzheimer's vaccine, which alone entered analytic trials a few canicule ago. In fact, we accept already bettered the business development expectations that were mentioned in the analysis."
The base for the company's success, the AFFITOME technology, enables scientists to actualize both molecules with actual specific bounden characteristics and molecules that alter in anatomy but display identical bounden characteristics. AFFiRiS has acclimated these strengths to advance the two Alzheimer's vaccines AD01 and AD02, both of which ambition the beta-amyloid protein believed to could cause Alzheimer's disease. However, AFFITOME technology can aswell be acclimated to ambition and adapt added animal ambition structures, such as the enzymes complex in lipid metabolism. Consequently, an adapted development from AFFiRiS could accommodate an able analysis for the boundless ache of atherosclerosis.
(MARKET) SIZE MATTERS
AFFiRiS is the aboriginal aggregation to auspiciously advance a accurate causal analysis advantage for two diseases that are acutely accepted in automated countries - an important acumen why the aggregation was singled out for acclaim in the study, as Michael Motschmann, Senior Fund Manager at MIG-Fonds, explains: "The appraisal looked actual carefully absolutely at the admeasurement of the abeyant markets and the abridgement of able therapies in these markets. These two key belief are aswell cornerstones of the activity action at AFFiRiS. The amount of the bazaar for AFFiRiS' able Alzheimer's analysis abandoned is estimated at EUR 15 billion. That is why we see acceptance such as that accorded by Lifescience-online not just as a acumen to be optimistic about approaching business development, but aswell as an accepting of our business action to date."
Contact for AFFiRiS GmbH:
Dr. Walter Schmidt
Campus Vienna Biocenter 2
A-1030 Vienna
Austria
T +43 / 1 / 798 15 75 - 10
E walter.schmidt@affiris.com
Copy Editing & Distribution:
PR&D - Public Relations for Research & Education
Campus Vienna Biocenter 2
A-1030 Vienna
Austria
T +43 / 1 / 505 70 44
E contact@prd.at
About AFFiRiS GmbH (as at April 2008):
AFFiRiS GmbH develops peptide-based vaccines for the analysis of Alzheimer's disease, atherosclerosis and added austere diseases. The aggregation has accustomed its AFFITOME belvedere technology. It employs 30 awful able associates of agents on 600 sqm of busy class accessories at the Campus Vienna Biocenter (www.affiris.com).
AFFITOPE and AFFITOME are registered trademarks of Affiris GmbH.
About MIG-Fonds:
The accord of MIG Verwaltungs AG in Affiris GmbH represents the assiduity of a tried-and-tested approach. Investment is alone fabricated in called companies in Germany and Austria afterwards their activity has been thoroughly audited. Their innovative, high-potential articles and the ambitious abilities of their administration teams are both key. MIG Verwaltungs AG is accurate by Alfred Wieder AG. This specialist in adventure basic is accomplished in the auction of backing and is accordingly the aboriginal point of acquaintance for any abeyant investors.
Affiris - AFFiRiS - MIG-FONDS INCREASES INVESTMENT BY EURO 3 MILLION
Vienna, 25 September 2008. The acknowledged advance of several vaccine programmes run by AFFiRiS GmbH has prompted broker MIG AG to access its investment in the company. It has set up two new funds - MIG 5 and MIG 7 - to accord clandestine investors in Germany and Austria the befalling to advance in this able biotech company. The aggregation absitively to crop this footfall for two reasons. First, to ensure the aboriginal advantage of approaching basic appeal for the connected acknowledged development of vaccines adjoin Alzheimer's ache and atherosclerosis and, second, the amazing abeyant that the proprietary AFFITOME belvedere technology offers the all-around biologic market.
The investment accumulation MIG-Fonds appear today that it has added its investment in AFFiRiS by a added Euro 3 million. As a result, clandestine investors now accept addition adventitious to allotment in the bread-and-butter success of the biotech aggregation via the MIG Fonds 5 and 7. This account is decidedly accordant for clandestine investors in Germany, who accept actual acceptance to MIG 7. This provides investors with the befalling to accomplish a awful able investment afore the adapted basic assets tax comes into force in Germany. Therefore, afterwards a year's captivation period, any after profits fabricated from this investment will be tax free.
AFFiRiS will accord to the success of these funds through its proprietary AFFITOME technology, which is based on the action of atomic mimicry. This technology enables the development of customized vaccines accepted as AFFITOPE. Dr. Walter Schmidt, co-founder and aggregation CEO, explains the key to the company's AFFiRiS vaccine strategy: "Our patented AFFITOME technology enables scientists to actualize both molecules with actual specific bounden characteristics and molecules that alter in anatomy but display identical bounden characteristics. We are currently application these strengths in the development of vaccines adjoin Alzheimer's disease. In the future, AFFITOME technology will aswell be able to apply a absolute access on added animal rogue proteins - such as lipid metabolism enzymes. In band with our action of developing medicines for diseases with burning medical charge and adorable bazaar potential, one of our next artefact candidates can bear able after-effects in the analysis of atherosclerosis."
Michael Motschmann, Senior Fund Manager at MIG Fonds, comments on business developments at AFFiRiS GmbH: "In an amazingly abbreviate aeon of time, the aggregation has developed two vaccines adjoin Alzheimer's ache from the antecedent abstraction to the aboriginal appearance I analytic trial, appropriately underlining the capability of its awful able business model. We accept every acumen to accept that these vaccines accomplish absorbing artefact candidates and apprehend commensurable developments to chase in added indications. This advance abandoned prompted us to accomplish addition abundant investment. What's more, the AFFITOME technology abaft the development of these vaccines represents an about costive value, which can accomplish the aggregation a actual adorable licenser for above biologic companies."
About AFFiRiS GmbH (as at September 2008):
AFFiRiS GmbH develops peptide-based vaccines for the analysis of Alzheimer's disease, atherosclerosis and added diseases that actively crave a medical solution. The aggregation has accustomed belvedere technologies and registered the agnate apparent families. The aboriginal patents accept already been issued. It employs 35 awful able associates of agents on 600sqm of busy class accessories at the Campus Vienna Biocenter (www.affiris.com).
About MIG-Fonds:
The accord of MIG Verwaltungs AG in Affiris GmbH represents the assiduity of a tried-and-tested approach. Investment is alone fabricated in called companies in Germany and Austria afterwards their activity has been thoroughly audited. Its innovative, high-potential articles and the ambitious abilities of its administration teams are both key. MIG Verwaltungs AG is accurate by Alfred Wieder AG. This specialist in adventure basic is accomplished in the auction of backing and is accordingly the aboriginal point of acquaintance for any abeyant investors.
Contact for AFFiRiS GmbH:
Dr. Walter Schmidt
Campus Vienna Biocenter 2
1030 Vienna
Austria
T +43 / 1 / 798 15 75-10
E office@affiris.com
Copy Editing & Distribution:
PR&D - Public Relations for Research & Education
Campus Vienna Biocenter 2
1030 Vienna
Austria
T +43 / 1 / 505 70 44
E contact@prd.at
W www.prd.at
The investment accumulation MIG-Fonds appear today that it has added its investment in AFFiRiS by a added Euro 3 million. As a result, clandestine investors now accept addition adventitious to allotment in the bread-and-butter success of the biotech aggregation via the MIG Fonds 5 and 7. This account is decidedly accordant for clandestine investors in Germany, who accept actual acceptance to MIG 7. This provides investors with the befalling to accomplish a awful able investment afore the adapted basic assets tax comes into force in Germany. Therefore, afterwards a year's captivation period, any after profits fabricated from this investment will be tax free.
AFFiRiS will accord to the success of these funds through its proprietary AFFITOME technology, which is based on the action of atomic mimicry. This technology enables the development of customized vaccines accepted as AFFITOPE. Dr. Walter Schmidt, co-founder and aggregation CEO, explains the key to the company's AFFiRiS vaccine strategy: "Our patented AFFITOME technology enables scientists to actualize both molecules with actual specific bounden characteristics and molecules that alter in anatomy but display identical bounden characteristics. We are currently application these strengths in the development of vaccines adjoin Alzheimer's disease. In the future, AFFITOME technology will aswell be able to apply a absolute access on added animal rogue proteins - such as lipid metabolism enzymes. In band with our action of developing medicines for diseases with burning medical charge and adorable bazaar potential, one of our next artefact candidates can bear able after-effects in the analysis of atherosclerosis."
Michael Motschmann, Senior Fund Manager at MIG Fonds, comments on business developments at AFFiRiS GmbH: "In an amazingly abbreviate aeon of time, the aggregation has developed two vaccines adjoin Alzheimer's ache from the antecedent abstraction to the aboriginal appearance I analytic trial, appropriately underlining the capability of its awful able business model. We accept every acumen to accept that these vaccines accomplish absorbing artefact candidates and apprehend commensurable developments to chase in added indications. This advance abandoned prompted us to accomplish addition abundant investment. What's more, the AFFITOME technology abaft the development of these vaccines represents an about costive value, which can accomplish the aggregation a actual adorable licenser for above biologic companies."
About AFFiRiS GmbH (as at September 2008):
AFFiRiS GmbH develops peptide-based vaccines for the analysis of Alzheimer's disease, atherosclerosis and added diseases that actively crave a medical solution. The aggregation has accustomed belvedere technologies and registered the agnate apparent families. The aboriginal patents accept already been issued. It employs 35 awful able associates of agents on 600sqm of busy class accessories at the Campus Vienna Biocenter (www.affiris.com).
About MIG-Fonds:
The accord of MIG Verwaltungs AG in Affiris GmbH represents the assiduity of a tried-and-tested approach. Investment is alone fabricated in called companies in Germany and Austria afterwards their activity has been thoroughly audited. Its innovative, high-potential articles and the ambitious abilities of its administration teams are both key. MIG Verwaltungs AG is accurate by Alfred Wieder AG. This specialist in adventure basic is accomplished in the auction of backing and is accordingly the aboriginal point of acquaintance for any abeyant investors.
Contact for AFFiRiS GmbH:
Dr. Walter Schmidt
Campus Vienna Biocenter 2
1030 Vienna
Austria
T +43 / 1 / 798 15 75-10
E office@affiris.com
Copy Editing & Distribution:
PR&D - Public Relations for Research & Education
Campus Vienna Biocenter 2
1030 Vienna
Austria
T +43 / 1 / 505 70 44
E contact@prd.at
W www.prd.at
AFFiRiS AG - AFFiRiS AG: 1st Place in Venture Capital & Private Equity Awards for MIG Fonds and AFFiRiS
Vienna, 23rd June 2009. MIG Fonds and AFFiRiS AG are this year's winners of the 2009 Venture Capital & Private Equity accolade antagonism hosted by the industry annual Boerse-Express and Junge Industrie. The accolade recognised the abiding affiliation amid the German adventure armamentarium and the Austrian biotechnology aggregation as able-bodied as a EUR 430 actor accord amid AFFiRiS and GSK Biologicals.
Last Tuesday MIG Fonds and AFFiRiS AG were awarded aboriginal abode in the Venture Capital and Private Equity (VC / PE) awards of the Austrian industry annual Boerse-Express.com and their co-sponsors Junge Industrie. The winners are called afterward a appropriate alternative action that combines the perspectives of the magazine's readers and called experts, who appraise accumulated success belief from altered perspectives. This year, an investment accord that has been abounding for both adventure ally was recognised and the accent of VC costs for the start-up aeon of avant-garde businesses was thereby recognised.
Dr. Walter Schmidt, co-founder and CEO of AFFiRiS AG, commented that the VC / PE awards "have a actual appropriate acceptation for the basic investment bazaar in Austria because they authenticate the basic action of VC in the development of able high-tech businesses. In our case, three years ago MIG Fonds started to advance a absolute of EUR 11.5 million. Without this capital, our licensing accord with GSK Biologicals three years after would not accept been possible. This accord is for up to EUR 430 actor in upfront and anniversary payments for our Alzheimer’s vaccines. MIG Fonds' accommodation to advance has accordingly already been amiable for anybody involved."
Based on the MIG Fonds investment, AFFiRiS AG was able to advance ist AFFITOME® technology, which delivers avant-garde vaccines with actual specific properties. The close has already appear the development of candidates for ameliorative vaccines adjoin Alzheimer's, Parkinson's and atherosclerosis - in added words, adjoin diseases that accept so far seemed clashing for analysis by vaccination, but that represent markets account billions. Vaccine candidates for four added bearding abiding diseases are currently accepting developed by AFFiRiS AG.
Asked about the success adventure of AFFiRiS AG and the accepted award, Andreas Höfler of Alfred Wieder AG said: "We are actual appreciative of this award. Good investment tends to not alone advance advances in technology, but aswell to advance individuals and aims that are as abstracted as they are clear. Our MIG armamentarium managers aswell pay accurate absorption to ensuring that the ambition markets of our abeyant investees are of a acceptable size, and that the businesses we accounts accept the abeyant to become all-embracing bazaar leaders. We recognised this abeyant in AFFiRiS three years ago - the aboriginal big pharma accord and the accepted accolade affirm our antecedent analysis."
About AFFiRiS AG (as at June 2009)
AFFiRiS AG develops customised peptide-based vaccines based on its own patents. These are acclimated to amusement Alzheimer's disease, atherosclerosis, Parkinson's ache and added diseases that actively crave a medical band-aid and which accept ample bazaar potential. Alzheimer's ache is currently the arch adumbration and two abeyant articles are in the final stages of analytic appearance I studies. In October 2008, the aggregation succeeded in accepting GlaxoSmithKline Biologicals as its licensing accomplice for the Alzheimer's vaccine. The arrangement anticipates milestone-dependent
payments of up to EUR 430 million. AFFiRiS currently employs 50 awful able agents and afresh added an added 1,100 sqm to its bounds at the St. Marx campus in Vienna, Austria (www.affiris.com).
Contact for AFFiRiS AG:
Mag. Agnes Meyer
Karl-Farkas-Gasse 22
1030 Vienna
Austria
T +43 / 1 / 798 15 75 - 390
E agnes.meyer@affiris.com
Copy Editing & Distribution:
PR&D - Public Relations for Research & Education
Campus Vienna Biocenter 2
1030 Vienna
Austria
T +43 / 1 / 505 70 44
E contact@prd.at
Last Tuesday MIG Fonds and AFFiRiS AG were awarded aboriginal abode in the Venture Capital and Private Equity (VC / PE) awards of the Austrian industry annual Boerse-Express.com and their co-sponsors Junge Industrie. The winners are called afterward a appropriate alternative action that combines the perspectives of the magazine's readers and called experts, who appraise accumulated success belief from altered perspectives. This year, an investment accord that has been abounding for both adventure ally was recognised and the accent of VC costs for the start-up aeon of avant-garde businesses was thereby recognised.
Dr. Walter Schmidt, co-founder and CEO of AFFiRiS AG, commented that the VC / PE awards "have a actual appropriate acceptation for the basic investment bazaar in Austria because they authenticate the basic action of VC in the development of able high-tech businesses. In our case, three years ago MIG Fonds started to advance a absolute of EUR 11.5 million. Without this capital, our licensing accord with GSK Biologicals three years after would not accept been possible. This accord is for up to EUR 430 actor in upfront and anniversary payments for our Alzheimer’s vaccines. MIG Fonds' accommodation to advance has accordingly already been amiable for anybody involved."
Based on the MIG Fonds investment, AFFiRiS AG was able to advance ist AFFITOME® technology, which delivers avant-garde vaccines with actual specific properties. The close has already appear the development of candidates for ameliorative vaccines adjoin Alzheimer's, Parkinson's and atherosclerosis - in added words, adjoin diseases that accept so far seemed clashing for analysis by vaccination, but that represent markets account billions. Vaccine candidates for four added bearding abiding diseases are currently accepting developed by AFFiRiS AG.
Asked about the success adventure of AFFiRiS AG and the accepted award, Andreas Höfler of Alfred Wieder AG said: "We are actual appreciative of this award. Good investment tends to not alone advance advances in technology, but aswell to advance individuals and aims that are as abstracted as they are clear. Our MIG armamentarium managers aswell pay accurate absorption to ensuring that the ambition markets of our abeyant investees are of a acceptable size, and that the businesses we accounts accept the abeyant to become all-embracing bazaar leaders. We recognised this abeyant in AFFiRiS three years ago - the aboriginal big pharma accord and the accepted accolade affirm our antecedent analysis."
About AFFiRiS AG (as at June 2009)
AFFiRiS AG develops customised peptide-based vaccines based on its own patents. These are acclimated to amusement Alzheimer's disease, atherosclerosis, Parkinson's ache and added diseases that actively crave a medical band-aid and which accept ample bazaar potential. Alzheimer's ache is currently the arch adumbration and two abeyant articles are in the final stages of analytic appearance I studies. In October 2008, the aggregation succeeded in accepting GlaxoSmithKline Biologicals as its licensing accomplice for the Alzheimer's vaccine. The arrangement anticipates milestone-dependent
payments of up to EUR 430 million. AFFiRiS currently employs 50 awful able agents and afresh added an added 1,100 sqm to its bounds at the St. Marx campus in Vienna, Austria (www.affiris.com).
Contact for AFFiRiS AG:
Mag. Agnes Meyer
Karl-Farkas-Gasse 22
1030 Vienna
Austria
T +43 / 1 / 798 15 75 - 390
E agnes.meyer@affiris.com
Copy Editing & Distribution:
PR&D - Public Relations for Research & Education
Campus Vienna Biocenter 2
1030 Vienna
Austria
T +43 / 1 / 505 70 44
E contact@prd.at
订阅：
博文 (Atom)